These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 22312009

  • 1. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D, Giovannoni G.
    Pract Neurol; 2012 Feb 17; 12(1):25-35. PubMed ID: 22258169
    [Abstract] [Full Text] [Related]

  • 5. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 17; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 6. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 17; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 7. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 17; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

  • 8. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 9. Advances in the management of PML: focus on natalizumab.
    Fox R.
    Cleve Clin J Med; 2011 Nov 01; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [Abstract] [Full Text] [Related]

  • 10. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ, Hogg JP.
    Curr Opin Neurol; 2013 Jun 01; 26(3):318-23. PubMed ID: 23493158
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar 01; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 12. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 13. Anti-JC virus antibodies: implications for PML risk stratification.
    Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M.
    Ann Neurol; 2010 Sep 30; 68(3):295-303. PubMed ID: 20737510
    [Abstract] [Full Text] [Related]

  • 14. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
    Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.
    Arch Neurol; 2007 Feb 30; 64(2):169-76. PubMed ID: 17296831
    [Abstract] [Full Text] [Related]

  • 15. The link between VLA-4 and JC virus reactivation.
    Monaco MC, Major EO.
    Expert Rev Clin Immunol; 2012 Jan 30; 8(1):63-72. PubMed ID: 22149341
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab: risk stratification of individual patients with multiple sclerosis.
    Tur C, Montalban X.
    CNS Drugs; 2014 Jul 30; 28(7):641-8. PubMed ID: 24942634
    [Abstract] [Full Text] [Related]

  • 17. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 30; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 18. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 30; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 19. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC, Hecht EM.
    Clin Neuropharmacol; 2014 Jun 30; 37(2):45-51. PubMed ID: 24614671
    [Abstract] [Full Text] [Related]

  • 20. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2014 Jan 30; 20(1):108-11. PubMed ID: 23828867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.